RE:MDP is undervalued and that puzzles meMDP is very undervalued. I think once they list on the Nasdaq and US institutions get involved, things will get better. The stock price should be $15 now imo based on their growth. The company should do a better job at PR to get investors in this one. Right now they are on track to do about $120+ million in revenue. In August, if they get approval for Treosulfan (sp?), that could add another $150 million+ in revenues. Couple that with their current product mix that is growing and more to come, the company could be generating $400-$500+ million in a few years. The market cap right now is about $125 million. At a billion market cap, which is certainly doable, we are at about a $60/share price